CBD — Research Profile

No — CBD is non-psychoactive and does not produce the intoxication or euphoria associated with THC. Full-spectrum CBD products contain trace amounts of THC (less than 0.3% by law), but this is far too little to cause psychoactive effects. If you are concerned about any THC exposure (e.g., for drug testing), choose broad-spectrum or isolate products.

The CBD market has significant quality issues — studies have found many products contain less CBD than labeled, or contain unlisted THC. Look for: (1) third-party certificate of analysis (COA) from an independent lab, (2) NSF, USP, or ISO 17025-accredited testing, (3) clear labeling of CBD content per serving (not just hemp extract), and (4) extraction method (CO2 extraction is preferred). Avoid products that make therapeutic claims or lack transparency about testing.

Yes — this is a significant concern. CBD inhibits CYP3A4 and CYP2C19 liver enzymes, which metabolize approximately 60% of all pharmaceuticals. This can increase blood levels of statins, blood thinners, calcium channel blockers, benzodiazepines, and many other drugs. A practical rule: if your medication has a grapefruit warning, CBD may interact with it similarly. Always consult your pharmacist or physician before starting CBD if you take any regular medications.

No consumer form has been shown superior in head-to-head trials; the only product with proven efficacy is prescription purified CBD oral solution (Epidiolex). Full-spectrum, broad-spectrum, and isolate products differ mainly in whether trace THC and other hemp compounds are present, not in demonstrated benefit. Oral CBD has low bioavailability, and taking it consistently with respect to meals reduces swings in blood levels.

The best-established benefit is seizure reduction: purified CBD (Epidiolex) is FDA-approved for the rare epilepsies Dravet syndrome and Lennox-Gastaut syndrome. For anxiety, a 2024 meta-analysis of 8 trials (316 participants) found a moderate-to-large effect (Hedges' g = -0.92), supported by single-dose reductions in situational anxiety. Evidence for sleep is weaker and inconsistent, with reported improvements often uncertain or secondary to reduced anxiety.

No standardized over-the-counter dose is established, and effective amounts differ enormously by purpose. Controlled anxiety research used single oral doses around 300 mg, with 150 mg and 600 mg proving no better than placebo (a bell-shaped response), while prescription epilepsy dosing is weight-based and titrated to roughly 10-25 mg/kg/day. Most consumer products supply far less, often 10-50 mg, an amount not well studied for efficacy.

Time of day has not been directly compared in consumer studies, so it is guided by the goal. For situational anxiety, trial doses were taken about 1.5 hours before the stressor; for sleep, evening dosing is typical. Prescription CBD is taken twice daily and kept consistent with respect to meals to keep blood levels stable.

The most commonly reported effects are drowsiness or reduced alertness, mood changes, decreased appetite, and gastrointestinal symptoms such as diarrhea. More serious documented concerns include liver injury (dose-related transaminase elevations seen in epilepsy trials) and potential male reproductive harm. In people who also use THC, CBD products can add to cognitive impairment.

Yes, and this is CBD's most clinically important risk. It inhibits CYP3A4, CYP2C9, and CYP2C19, which can raise levels of drugs cleared by those enzymes, including the anticonvulsant clobazam (via CYP2C19) and the blood thinner warfarin (via CYP2C9). NCCIH specifically flags interactions with other drugs alongside liver injury, so anyone on prescription medication, especially drugs carrying a grapefruit warning, should check with a clinician first.

The clearest candidates are patients with the rare, drug-resistant epilepsies Dravet and Lennox-Gastaut syndromes, for whom prescription CBD is FDA-approved, and people with anxiety disorders, who have the most supportive though still limited trial evidence. It should generally be avoided in pregnancy and breastfeeding: the Epidiolex label warns it may cause fetal harm based on animal data (embryofetal mortality and reduced fetal growth) and notes there are no data on cannabidiol in human milk. It should also be avoided in liver disease and by anyone taking medications metabolized by CYP3A4 or CYP2C19, given the documented liver injury and drug-interaction risks.

Onset depends on the goal. For acute anxiety, single oral doses have reduced situational anxiety within roughly 1.5 hours in a controlled public-speaking trial, and in a psychiatric case series anxiety scores dropped within the first month in 79% of patients while sleep scores improved in 67%. For epilepsy, prescription CBD (Epidiolex) is not given at full strength on day one: its FDA label starts at 5 mg/kg/day and is raised in weekly increments to a 20-25 mg/kg/day maintenance dose, so seizure-control dosing is reached gradually over several weeks rather than immediately.

Most long-term daily data come from prescription CBD (Epidiolex) in epilepsy, where dose-related liver-enzyme elevations require periodic monitoring. NCCIH lists liver injury and possible male reproductive harm as documented risks, and a benchmark-dose analysis set a provisional chronic reference dose of just 4 mg/kg body weight per day. The safety of unregulated over-the-counter CBD used daily beyond a few months has not been well characterized.

Yes. A benchmark-dose toxicology analysis derived a provisional acute reference dose of 1 mg/kg body weight and a chronic reference dose of 4 mg/kg per day, based on liver and reproductive signals. Prescription Epidiolex is titrated far higher, to a maximum of 25 mg/kg/day, but only under medical supervision with liver-enzyme monitoring; excessive intake commonly causes sedation, diarrhea, and appetite loss.

CBD inhibits the cytochrome-P450 enzymes CYP3A4, CYP2C9, and CYP2C19, so it can raise blood levels of other compounds cleared by those pathways rather than acting in isolation. Stacking it with sedating supplements such as melatonin or valerian can compound its drowsiness and reduced alertness. No trial evidence shows that any CBD-plus-supplement combination improves outcomes.

Because over-the-counter CBD is not FDA-regulated, testing has repeatedly found products with inaccurate labeled CBD amounts, contaminants, or unlabeled THC. Look for a current third-party certificate of analysis that confirms the stated CBD content, verifies THC below 0.3%, and screens for solvents, pesticides, and heavy metals. Only prescription Epidiolex offers a guaranteed purified CBD concentration.